A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion After Oral Administration of [14C]-AZD3293 to Healthy Male Subjects

Trial Profile

A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion After Oral Administration of [14C]-AZD3293 to Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2014

At a glance

  • Drugs Lanabecestat (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Acronyms AZD3293 hADME
  • Sponsors AstraZeneca
  • Most Recent Events

    • 13 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 May 2014 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 05 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top